House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Obstetrics & gynaecology

Fertility problems: assessment and treatment

NICE · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG257 covers fertility assessment, cause-specific treatment, assisted conception and fertility preservation. Its updated recommendations distinguish tests that help plan treatment from tests that do not predict spontaneous pregnancy, restrict unsupported add-ons and set specific IVF access criteria. Care is inclusive of people with the relevant reproductive organs, with shared decisions around partner factors, age, treatment burden and future fertility.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Offer assessment and timely specialist referral

  • Offer an initial assessment for delayed conception, including lifestyle and sexual history, and a consultation on conception options when vaginal intercourse is impossible or very difficult. Create space for sensitive concerns. [1]
  • Without a suspected cause, investigate both partners after 1 year of unprotected vaginal intercourse without conception. With artificial insemination, investigate after 6 unsuccessful cycles and include the sperm-providing partner when partner sperm is used. [1]
  • Refer at presentation when the person trying to become pregnant is at least 36 or either partner has a known or suspected infertility cause or predisposing history. Expedite referral before treatment likely to impair fertility. [1]

Investigate male-factor fertility problems selectively

  • Confirm an abnormal semen analysis with repeat testing, ideally after 3 months, but sooner for azoospermia or severe oligozoospermia. After at least 2 abnormal analyses, offer scrotal and testicular examination and consider testosterone and gonadotrophins. [1]
  • Do not routinely test antisperm antibodies or test sperm DNA fragmentation. Test for Y-chromosome microdeletions in idiopathic azoospermia or sperm concentration below 1 million/mL, and test CFTR when idiopathic obstructive azoospermia or a vasal abnormality is suspected. [1]
  • Test karyotype in idiopathic azoospermia and consider it for persistently fewer than 5 million sperm/mL. Offer genetic counselling when a specific genetic cause of male-factor infertility is identified. [1]

Distinguish ovarian response from spontaneous fertility

  • Do not use AMH to predict spontaneous clinical pregnancy. Use AMH or antral follicle count to predict ovarian response and inform assisted-conception counselling; do not use FSH to predict ovarian response or assisted-conception outcome. [1]
  • Confirm ovulation with mid-luteal progesterone during infertility investigation, even with regular cycles. Time it to the cycle rather than automatically using a calendar day; prolonged irregular cycles may require later and repeated measurements. Do not rely on basal-temperature charts. [1]
  • Reserve prolactin measurement for ovulatory disorder, galactorrhoea or pituitary tumour, and thyroid tests for symptoms of thyroid disease. These are not routine screening tests for every person concerned about fertility. [1]
  • Offer HSG for tubal screening when relevant comorbidities such as pelvic inflammatory disease, previous ectopic pregnancy or endometriosis are absent; where expertise is available, consider contrast ultrasonography as an alternative. Offer laparoscopy with dye when pelvic comorbidity is suspected, and hysteroscopy only for a clinically suspected uterine or endometrial abnormality. [1]

Treat identified causes

  • Offer gonadotrophins for male hypogonadotropic hypogonadism. For abnormal semen parameters without that disorder, gonadotrophin or anti-oestrogen treatment belongs only in a trial; do not offer androgens or treatments aimed at improving sperm DNA fragmentation. [1]
  • For obstructive azoospermia, offer surgical correction or sperm retrieval, weighing partner fertility factors, obstruction duration, intervention risks and preferences. Offer retrieval for non-obstructive azoospermia and consider micro-TESE, but do not retrieve sperm with AZFa or AZFb deletion. [1]
  • For anovulatory hypogonadotropic hypogonadism, address low weight or excessive exercise and offer gonadotrophins with luteinising activity or GnRH for ovulation induction. Offer cabergoline for hyperprolactinaemic ovulatory disorder. [1]
  • Before gonadotrophin ovulation induction, discuss multiple pregnancy and ovarian hyperstimulation risk, and monitor follicle size and number with ultrasound. Before IVF, offer salpingectomy or tubal occlusion for hydrosalpinx; consider aspiration near retrieval if laparoscopic complication risk is high. [1]

Discuss unexplained infertility and IVF access

  • For unexplained infertility with regular unprotected intercourse, advise trying for a total of 2 years before treatment. Do not offer ovarian stimulation alone; after that interval discuss up to 4 gonadotrophin-stimulated IUI cycles before IVF or offer IVF, incorporating risks and preferences. [1]
  • NICE offers IVF before the 42nd birthday when a diagnosed cause cannot be successfully managed otherwise, unexplained infertility persists after 2 years, or 12 insemination cycles including at least 6 IUI cycles fail. Discuss ovarian reserve and treatment risks and benefits. [1]
  • For eligible people under 40, offer an initial 3 full IVF cycles and consider up to 3 more after discussing success chances and implications. Complete a current full cycle if the person turns 40 but do not start more. At ages 40–41, offer 1 full cycle only if eligible and never previously treated with IVF. [1]

Avoid unsupported add-ons and select procedures

  • Do not offer endometrial scratching, screening hysteroscopy to improve IVF outcomes, endometrial receptivity testing as an embryo-transfer add-on, or immunological agents such as intralipid, immunoglobulin or glucocorticoids as fertility treatment. [1]
  • Do not offer PGT-A to improve live-birth rates or assisted hatching to improve pregnancy rates. Use ultrasound-guided transfer, choose a single embryo when a top-quality blastocyst is available, and never transfer more than 2 embryos in one cycle. [1]
  • Offer ICSI with surgically retrieved sperm or frozen-thawed oocytes. Consider it for sufficiently abnormal semen or previous failed or very low fertilisation; do not use it for non-male-factor infertility with normal semen, or add IMSI or prefer PICSI to standard ICSI. [1]

Protect fertility before damaging treatment

  • Discuss preservation as early as possible before urgent treatment or when a condition threatens fertility. Offer sperm, oocyte or embryo cryopreservation as appropriate for reproductive-age patients; consider ovarian tissue preservation when oocyte or embryo storage is infeasible, including before puberty. [1]

Limitations and use

  • IVF cycle access and funding recommendations are from the UK NICE pathway; they are not a universal entitlement or an individual success prediction.
  • This selected summary omits detailed donor pathways and some reproductive-risk counselling. PCOS treatment recommendations were removed from this document pending a separate guideline; no PCOS ovulation-induction regimen is inferred.
  • Ovarian stimulation, triggering, luteal support and OHSS detail are cross-referenced to ESHRE rather than restated as a complete protocol here.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Fertility problems: assessment and treatment

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
31 March 2026
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Offer assessment and timely specialist referral
  • Investigate male-factor fertility problems selectively
  • Distinguish ovarian response from spontaneous fertility
  • Treat identified causes
  • Discuss unexplained infertility and IVF access
  • Avoid unsupported add-ons and select procedures
  • Protect fertility before damaging treatment
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House